Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Show other versions (1)

<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 150%; text-align: justify;"><span style="font-family: 'Times New Roman'; font-size: medium;"><span style="font-size: 16px; line-height: 24px;">No...

Full description

Bibliographic Details
Main Authors: Bernadene Fernandopulle, Alhossain A. Khalafallah, Terry Brain
Format: Article
Language:English
Published: PAGEPress Publications 2010-05-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Intermediate, high-risk MDS
IPSS
lenalidomide
hematological response
dose-modified.
Online Access:http://www.mjhid.org/article/view/5801

Internet

http://www.mjhid.org/article/view/5801

Similar Items